Henlius Shows Strong Growth in 2026 Interim Results with Sustainable Profitability and Global Strategy

Henlius Reports 2026 Interim Results

On August 21, 2026, Henlius (2696.HK), a leading biopharmaceutical company based in Shanghai, announced its interim financial results for the fiscal year 2026. The report demonstrated remarkable growth, showcasing a year-on-year revenue increase of 27.3%, totaling RMB 3.5882 billion, and a net profit of RMB 430.4 million, reflecting a 10.3% rise compared to the previous year. The company also reported a non-IFRS profit of RMB 572.3 million, representing an impressive 46.7% increase.

Strong Growth Momentum

Henlius's sustained organic growth and resilient earnings are attributed to its robust operational framework, which encompasses lean management across its entire value chain. Dr. Jason Zhu, the Executive Director and CEO of Henlius, emphasized that 2026 is a pivotal year in their mission to evolve into a China-based Multinational Company (C-MNC). The core products of the company are increasingly gaining traction in the global market, with numerous pipeline assets entering critical phases of value validation.

The company has made significant strides in addressing unmet patient needs through global commercialization efforts, reinforcing its commitment to innovation. Henlius now boasts 10 products approved in over 60 countries and regions, successfully impacting more than 1.1 million patients worldwide. Notably, sales revenue from markets outside of China saw a staggering increase of 159.4% compared to the previous year, evidencing the company's expanding footprint.

Advancing Global Commercialization

Henlius's strategic focus on key therapeutic areas such as breast cancer, lung cancer, and gastrointestinal cancers has produced substantial results. The sales revenue from its breast cancer portfolio alone reached RMB 1.6983 billion, showcasing the company's leadership in this critical domain.

Products like HANQUYOU (trastuzumab) and HANBEIYOU (pertuzumab) have been at the forefront of their strategy, with HANBEIYOU recently gaining marketing approvals across major markets, including the U.S., EU, and China. This achievement not only establishes Henlius as a pioneer in the biosimilar market but also represents a significant step in expanding treatment options for breast cancer patients.

Furthermore, the company is enriching its breast cancer pipeline with innovative therapies aimed at addressing various stages of the disease, emphasizing its commitment to providing comprehensive treatment solutions.

Innovations and Collaborations

Henlius is also making considerable advances in solid tumor indications, with products like Serplulimab (Hetronifly®) gaining momentum. This anti-PD-1 monoclonal antibody has been integral in fulfilling unmet patient needs, especially after receiving approval for the perioperative treatment of gastric cancer, establishing it as a groundbreaking product.

The company’s collaboration strategies have bolstered its globalization efforts. Recent partnerships with prominent organizations, such as Eisai Co., Ltd., and Abbott, aim to enhance its commercial footprint across Asia-Pacific and emerging markets, underpinning its Globalization 2.0 strategy. Henlius remains focused on maximizing the global potential of its biosimilar portfolio through synchronized development pathways in China and the U.S.

A Bright Future Ahead

Looking forward, Henlius plans to continue its innovation-driven growth, aspiring to launch 10 new products and establish itself as a globally renowned biopharmaceutical company by 2030. With robust RD investment and an agile commercialization model, the company is in a prime position to create sustainable value for patients and stakeholders alike.

As Henlius accelerates its journey towards becoming a C-MNC, the company is well-prepared to navigate the complexities of the global biopharmaceutical landscape, all while remaining dedicated to its mission of delivering high-quality, affordable therapies to patients around the world. The momentum generated by its strategic initiatives heralds an exciting chapter for Henlius, as it aims to make a meaningful impact on global health.

To learn more about Henlius, visit their official website and stay connected through their social media platforms.